172 related articles for article (PubMed ID: 34712735)
1. Protein Arginine Methyltransferase 5 Promotes the Migration of AML Cells by Regulating the Expression of Leukocyte Immunoglobulin-Like Receptor B4.
Zhao L; Cheng B; Xiong J; Ma D; Liu X; Wang L; Zhang X; Wang J
Biomed Res Int; 2021; 2021():7329072. PubMed ID: 34712735
[TBL] [Abstract][Full Text] [Related]
2. Leukocyte immunoglobulin-like receptor B1 and B4 (LILRB1 and LILRB4): Highly sensitive and specific markers of acute myeloid leukemia with monocytic differentiation.
Churchill HRO; Fuda FS; Xu J; Deng M; Zhang CC; An Z; Zhang N; Chen P; Bergstrom C; Kansagra A; Collins R; John S; Koduru P; Chen W
Cytometry B Clin Cytom; 2021 Jul; 100(4):476-487. PubMed ID: 32918786
[TBL] [Abstract][Full Text] [Related]
3. Selective PRMT5 Inhibitors Suppress Human CD8
Strobl CD; Schaffer S; Haug T; Völkl S; Peter K; Singer K; Böttcher M; Mougiakakos D; Mackensen A; Aigner M
Mol Cancer Ther; 2020 Feb; 19(2):409-419. PubMed ID: 31712395
[TBL] [Abstract][Full Text] [Related]
4. The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation.
Tarighat SS; Santhanam R; Frankhouser D; Radomska HS; Lai H; Anghelina M; Wang H; Huang X; Alinari L; Walker A; Caligiuri MA; Croce CM; Li L; Garzon R; Li C; Baiocchi RA; Marcucci G
Leukemia; 2016 Apr; 30(4):789-99. PubMed ID: 26536822
[TBL] [Abstract][Full Text] [Related]
5. PRMT5 promotes epithelial-mesenchymal transition via EGFR-β-catenin axis in pancreatic cancer cells.
Ge L; Wang H; Xu X; Zhou Z; He J; Peng W; Du F; Zhang Y; Gong A; Xu M
J Cell Mol Med; 2020 Jan; 24(2):1969-1979. PubMed ID: 31851779
[TBL] [Abstract][Full Text] [Related]
6. The PAF complex regulation of Prmt5 facilitates the progression and maintenance of MLL fusion leukemia.
Serio J; Ropa J; Chen W; Mysliwski M; Saha N; Chen L; Wang J; Miao H; Cierpicki T; Grembecka J; Muntean AG
Oncogene; 2018 Jan; 37(4):450-460. PubMed ID: 28945229
[TBL] [Abstract][Full Text] [Related]
7. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma.
Holmes B; Benavides-Serrato A; Saunders JT; Landon KA; Schreck AJ; Nishimura RN; Gera J
J Neurooncol; 2019 Oct; 145(1):11-22. PubMed ID: 31473880
[TBL] [Abstract][Full Text] [Related]
8. Targeting PRMT5/Akt signalling axis prevents human lung cancer cell growth.
Zhang S; Ma Y; Hu X; Zheng Y; Chen X
J Cell Mol Med; 2019 Feb; 23(2):1333-1342. PubMed ID: 30461193
[TBL] [Abstract][Full Text] [Related]
9. A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia.
Chiarini F; Lonetti A; Teti G; Orsini E; Bressanin D; Cappellini A; Ricci F; Tazzari PL; Ognibene A; Falconi M; Pagliaro P; Iacobucci I; Martinelli G; Amadori S; McCubrey JA; Martelli AM
Oncotarget; 2012 Dec; 3(12):1615-28. PubMed ID: 23271044
[TBL] [Abstract][Full Text] [Related]
10. The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement.
Bergstrom CP; Dahiya S; Chen W; Zhang CC; Zhu H; Yan J; Madanat Y; Patel P; Vusirkala M; Ramakrishnan P; Rizvi S; Chung S; Awan F; Anderson LD; Collins R; Kansagra A
Leuk Res; 2021 Jan; 100():106480. PubMed ID: 33285315
[TBL] [Abstract][Full Text] [Related]
11. Nucleophosmin Mutants Promote Adhesion, Migration and Invasion of Human Leukemia THP-1 Cells through MMPs Up-regulation via Ras/ERK MAPK Signaling.
Xian J; Shao H; Chen X; Zhang S; Quan J; Zou Q; Jin H; Zhang L
Int J Biol Sci; 2016; 12(2):144-55. PubMed ID: 26884713
[TBL] [Abstract][Full Text] [Related]
12. PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells.
Zhu F; Guo H; Bates PD; Zhang S; Zhang H; Nomie KJ; Li Y; Lu L; Seibold KR; Wang F; Rumball I; Cameron H; Hoang NM; Yang DT; Xu W; Zhang L; Wang M; Capitini CM; Rui L
Leukemia; 2019 Dec; 33(12):2898-2911. PubMed ID: 31123343
[TBL] [Abstract][Full Text] [Related]
13. Protein arginine methyltransferase 5 (PRMT5) promotes survival of lymphoma cells via activation of WNT/β-catenin and AKT/GSK3β proliferative signaling.
Chung J; Karkhanis V; Baiocchi RA; Sif S
J Biol Chem; 2019 May; 294(19):7692-7710. PubMed ID: 30885941
[TBL] [Abstract][Full Text] [Related]
14. Role of protein arginine methyltransferase 5 in inflammation and migration of fibroblast-like synoviocytes in rheumatoid arthritis.
Chen D; Zeng S; Huang M; Xu H; Liang L; Yang X
J Cell Mol Med; 2017 Apr; 21(4):781-790. PubMed ID: 27860244
[TBL] [Abstract][Full Text] [Related]
15. PRMT5 promotes cancer cell migration and invasion through the E2F pathway.
Barczak W; Jin L; Carr SM; Munro S; Ward S; Kanapin A; Samsonova A; La Thangue NB
Cell Death Dis; 2020 Jul; 11(7):572. PubMed ID: 32709847
[TBL] [Abstract][Full Text] [Related]
16. PRMT5 methylome profiling uncovers a direct link to splicing regulation in acute myeloid leukemia.
Radzisheuskaya A; Shliaha PV; Grinev V; Lorenzini E; Kovalchuk S; Shlyueva D; Gorshkov V; Hendrickson RC; Jensen ON; Helin K
Nat Struct Mol Biol; 2019 Nov; 26(11):999-1012. PubMed ID: 31611688
[TBL] [Abstract][Full Text] [Related]
17. Simvastatin regulates the proliferation, apoptosis, migration and invasion of human acute myeloid leukemia cells via miR-19a-3p/HIF-1α axis.
Tian H; Qiang T; Wang J; Ji L; Li B
Bioengineered; 2021 Dec; 12(2):11898-11908. PubMed ID: 34895042
[TBL] [Abstract][Full Text] [Related]
18. LILRB4-targeting Antibody-Drug Conjugates for the Treatment of Acute Myeloid Leukemia.
Anami Y; Deng M; Gui X; Yamaguchi A; Yamazaki CM; Zhang N; Zhang CC; An Z; Tsuchikama K
Mol Cancer Ther; 2020 Nov; 19(11):2330-2339. PubMed ID: 32879051
[TBL] [Abstract][Full Text] [Related]
19. Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma.
Chaturvedi NK; Mahapatra S; Kesherwani V; Kling MJ; Shukla M; Ray S; Kanchan R; Perumal N; McGuire TR; Sharp JG; Joshi SS; Coulter DW
BMC Cancer; 2019 Nov; 19(1):1056. PubMed ID: 31694585
[TBL] [Abstract][Full Text] [Related]
20. Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison.
Nepstad I; Hatfield KJ; Aasebø E; Hernandez-Valladares M; Brenner AK; Bartaula-Brevik S; Berven F; Selheim F; Skavland J; Gjertsen BT; Reikvam H; Bruserud Ø
Expert Opin Ther Targets; 2018 Jul; 22(7):639-653. PubMed ID: 29889583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
